Aims-To determine whether the presence of anticardiolipin antibodies in patients with suspected myocardial infarction is predictive of complications during hospital stay or after discharge. Methods-Anticardiolipin antibodies were serially measured in a cohort of 111 patients, from the time of admission to the coronary care unit till eight weeks after discharge. Associations with fatal and non-fatal cardiac complications were documented. Results-The incidence of raised titres of IgG and IgM anticardiolipin antibodies (ACA) in patients with myocardial infarction was comparable with that in patients with ischaemic heart disease. ACA titres in patients with a previous myocardial infarct were not significantly different from those found in patients without a previous history of infarction. Over the period of the study, ACA titres in the myocardial infarct group did not change significantly from those recorded on admission, nor did those patients with raised ACA titres have a higher prevalence of complications in hospital or in the early period after discharge. Conclusions-There is no evidence that patients with an acute or previous myocardial infarct have higher ACA titres than those found in patients with ischaemic heart disease. Raised ACA titres soon after myocardial infarction do not influence immediate patient outcome.
S
Heart, Lung and CirculationAbstracts S223 2011;20S:S156-S251 up and echo. Diagnosis of MFS by Ghent criteria. Bicuspid aortic valve (BAV) diagnosed by echo. Mean follow-up was 10 ± 8 years.Results: Patients with non-MFS TAAD presented later but had similar severity of aortic dilation. Major adverse cardiac events (MACE = dissection, surgery or death) were similar in MFS and non-MFS TAAD but first MACE occurred at younger age in MFS. Death rates and age of death were comparable between MFS and non-MFS TAAD.
MFS+ve BAV +ve MFS/BAV −ve p Number 176 53 153 Age enrolled Yrs 24.6 ± 13.9 42.8 ± 15.5 43.4 ± 18.3 <0.01 Ao diameter mm/m 2 28.6 ± 3.4 22.3 ± 4.3 29.3 ± 2.7 Family history % 62 21 53 MACE % 39 53 44 Age MACE Yrs 32.8 ± 12.5 47.4 ± 13.2 49.1 ± 16.7 <0.01 Deaths % 12 6 9 Age death Yrs 51.2 ± 10.7 54 ± 7.8 56.8 ± 13.7Conclusions: Non-MFS TAAD presents later but has adverse outcomes similar to MFS, although MACE occur later in non-MFS TAAD. Family history is common. Screening of first-degree relatives and active surveillance and intervention are warranted as per patients with MFS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.